Literature DB >> 1499942

Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.

C Cederberg1, A B Thomson, V Mahachai, J A Westin, P Kirdeikis, D Fisher, L Zuk, B Marriage.   

Abstract

Nine patients with duodenal ulcer were on separate occasions given omeprazole, 20 mg orally, 10 mg intravenously (IV), and 40 mg IV once daily for 5 days. On day 1, the median reduction of 24-hour intragastric acidity was 42.2% for the 20-mg oral dose and 54.8% and 88.4% for the two IV doses, respectively, but the between-patient variability was considerable for all three doses. On day 5, the degree of reduction had increased for all three doses to a median value of 99.9% for the 20-mg oral dose and 95.7% and 99.9% for the two IV doses, respectively. Plasma omeprazole concentrations increased significantly from day 1 to day 5 only for the 20-mg oral and 40-mg IV doses. Thus, the increased pharmacological effect of omeprazole during repeated once daily administration can only partly be explained by increased plasma concentrations, suggesting that some additional factor(s) must influence the degree of reduction of 24-hour intragastric acidity. Thus, when determining the optimal dose of omeprazole for acid inhibition, the route and duration of administration must be taken into consideration; after 5 days of once-daily administration of doses as low as 10 mg IV and 20 mg orally are effective and dependable in reducing 24-hour intragastric acidity in patients with duodenal ulcer. However, a daily dose of 40 mg IV omeprazole is not sufficient to keep intragastric pH above 4 in all patients during the first day of treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499942     DOI: 10.1016/0016-5085(92)90025-t

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Is oral combination therapy with a proton-pump inhibitor and H2 receptor antagonist effective as initial treatment?

Authors:  Masahiko Inamori; Keiko Akimoto; Tomoyuki Akiyama; Koji Fujita; Hirokazu Takahashi; Masato Yoneda; Yasunobu Abe; Hiroyuki Kirikoshi; Kensuke Kubota; Satoru Saito; Norio Ueno; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

Review 2.  Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

Authors:  J Labenz; P Malfertheiner
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

Review 3.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

4.  Stress-related Mucosal Disease.

Authors:  Mitchell J. Spirt
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

5.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

Authors:  M Chang; G Tybring; M L Dahl; E Götharson; M Sagar; R Seensalu; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

6.  Eosinophilic esophagitis: interactions with gastroesophageal reflux disease.

Authors:  Edaire Cheng; Rhonda F Souza; Stuart Jon Spechler
Journal:  Gastroenterol Clin North Am       Date:  2014-03-24       Impact factor: 3.806

7.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

Review 8.  Proton pump inhibitors for eosinophilic oesophagitis.

Authors:  Edaire Cheng
Journal:  Curr Opin Gastroenterol       Date:  2013-07       Impact factor: 3.287

Review 9.  Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications.

Authors:  Ramalinga R Kedika; Rhonda F Souza; Stuart Jon Spechler
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

10.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.